doi: 10.1016/j.chembiol.2019.01.008 133 LouandreCEzzoukhryZGodinCBarbareJCMaziereJCChauffertBet al
At 1aesthetic, were committed to helping you achieve the best version of yourself
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Disclosures: Niki Wadhwa: Nothing to Disclose, Kevin Houston: Nothing to Disclose, Hiba Khan: Nothing to Disclose, Hasan Alroobi: Nothing to Disclose, Nikita Chadha: Nothing to Disclose, Chad Spencer: Nothing to Disclose, Richard Sterling: ABIM: GI Specialty Board, Abott: Grant/Research Support, AbbVie: Grant/Research Support, Roche: Grant/Research Support, Zydus: Grant/Research Support, GSK: Grant/Research Support, HCV Vax: Grant/Research Support, Gilead: Grant/Research Support, Amon Asgharpour: Madrigal: Advisor, Galectin: Clinical Endpoint Committee, Nicole Keller: Nothing to Disclose, Joel Wedd: Nothing to Disclose, Hannah Lee: Nothing to Disclose, Mohammad Siddiqui: AMRA: Advisor, 89Bio: Advisor, NovoNordisk: Grant/Research Support, Vaishali Patel: Nothing to Disclose, Sayed Obaidullah Aseem: Galmed Pharmaceuticals: Grant/Research Support, Vinay Kumaran: Nothing to Disclose, Seung Lee: Nothing to Disclose, Amit Sharma: Nothing to Disclose, Aamir Khan: Nothing to Disclose, Daisuke Imai: Nothing to Disclose, Marlon Levy: Nothing to Disclose, David Bruno: Nothing to Disclose 1363 POST-TRANSPLANT PREDICTORS AND OUTCOMES OF PERSISTENT CHOLESTASIS AFTER LIVER TRANSPLANTATION Aaroh Patel 1 Vaishali Patel 1 Alexis Kim 1 Rehan Razzaq 1 Madison Nguyen 2 Mohammad Siddiqui 1 , 1 Virginia Commonwealth University, 2 VCUHS Background: Liver transplantation (LT) is the only curative treatment for end-stage liver disease (ESLD)
